Alpa Laboratorie

Which are the latest news on Alpa Laboratorie?

Why is Alpa Laboratories Ltd falling/rising?

As of 05-Sep, Alpa Laboratories Ltd's stock price is at 63.48, reflecting a decline of -0.63%. The stock has underperformed significantly over various time frames, with a year-to-date drop of -17.97% and a one-year decline of -33.82%, indicating a bearish trend and reduced investor interest.

As of 05-Sep, Alpa Laboratories Ltd's stock price is falling, currently at 63.48, reflecting a change of -0.4 (-0.63%). The stock has underperformed its sector by -0.27% today and has been on a consecutive decline for the last two days, resulting in a total drop of -0.91% during this period. <BR><BR>Over the past week, the stock has shown a minimal decline of -0.03%, while its performance over the last month has been significantly worse, with a decrease of -5.39%, compared to a -2.44% drop in the Sensex. Year-to-date, the stock is down -17.97%, which is notably worse than the Sensex's decline of -10.21%. In the past year, Alpa Laboratories Ltd has experienced a substantial fall of -33.82%, while the Sensex has only decreased by -5.21%. <BR><BR>Additionally, the stock's moving averages indicate a concerning trend, as it is higher than the 5-day moving average but lower than the 20-day, 50-day, 100-day, and 200-day moving averages. This suggests a bearish trend in the stock's performance. Investor participation has also declined, with delivery volume dropping by -62.99% against the 5-day average, indicating reduced interest from investors. Overall, these factors contribute to the ongoing decline in Alpa Laboratories Ltd's stock price.

Who are in the management team of Alpa Laboratorie?

The management team of Alpa Laboratorie includes Chairman Mahendra Singh Chawla, Managing Director Paresh Chawla, and several executive directors, along with independent directors and Company Secretary Swati Bagh, overseeing the company's operations and governance.

The management team of Alpa Laboratorie includes the following individuals:<BR><BR>1. Mahendra Singh Chawla - Chairman & Executive Director<BR>2. Pravin C Shah - Executive Director<BR>3. Paresh Chawla - Managing Director<BR>4. Vitthal Kothana - Executive Director<BR>5. Sunil Valecha - Additional Director<BR><BR>Additionally, the board features several independent directors:<BR><BR>1. Sharad Chand Lunawat - Independent Director<BR>2. Devendra Baheti - Independent Director<BR>3. Krishna Das Malani - Independent Director<BR>4. Jyoti Jain - Independent Director<BR>5. Saket Baheti - Independent Director<BR>6. Pratibha Lunawat - Independent Director<BR><BR>Swati Bagh serves as the Company Secretary and Compliance Officer. This team is responsible for overseeing the company's operations and governance.

What does Alpa Laboratorie do?

Alpa Laboratories Ltd is a micro-cap pharmaceutical and biotechnology company founded in 1967, specializing in various pharmaceutical formulations. As of June 2026, it reported net sales of 24 Cr and a net profit of 1 Cr, with a market cap of INR 134 Cr.

Overview: <BR>Alpa Laboratories Ltd is a pharmaceutical and biotechnology company operating in the micro-cap market, specializing in the manufacture of various pharmaceutical formulations.<BR><BR>History: <BR>Alpa Laboratories was incorporated in 1967 as 'Alpa Laboratories Private Limited' on March 18, 1988. It was converted into a Public Limited Company on September 3, 1998. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 24 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 134 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 33.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.73 <BR>Return on Equity: 7.97% <BR>Price to Book: 0.72 <BR><BR>Contact Details: <BR>Address: 33/2 Pigdamber, A B Road Rau Indore Madhya Pradesh : 453446 <BR>Tel: 91-731-4294567 <BR>Email: is@alpalabs.com <BR>Website: http://www.alpalabs.in

Who are the peers of the Alpa Laboratorie?

Alpa Laboratorie's peers include Parnax Lab, Lactose (India), Bal Pharma, Kimia Bioscien., Krebs Biochem, Makers Labs., Pharmaids Pharma, Balaxi Pharma, and Vaishali Pharma. In terms of management risk, growth, and capital structure, Parnax Lab and Balaxi Pharma stand out positively, while Alpa Laboratorie's 1-year return is -33.56%, better than Pharmaids Pharma but lower than its other peers.

Peers: The peers of Alpa Laboratorie are Parnax Lab, Lactose (India), Bal Pharma, Kimia Bioscien., Krebs Biochem, Makers Labs., Pharmaids Pharma, Balaxi Pharma, and Vaishali Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Parnax Lab and Balaxi Pharma, while Average management risk is found at Bal Pharma and Alpa Laboratorie. Below Average management risk is present at Lactose (India), Kimia Bioscien., Makers Labs., Pharmaids Pharma, and Vaishali Pharma, and Krebs Biochem does not qualify. Growth is rated as Good at Parnax Lab, while Average growth is seen at Pharmaids Pharma, and the rest have Below Average growth. Capital Structure is Excellent at Balaxi Pharma, Good at Alpa Laboratorie, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Makers Labs. at 25.01%, while Pharmaids Pharma has the lowest at -46.61%. Alpa Laboratorie's own 1-year return is -33.56%, which is higher than Pharmaids Pharma but lower than all other peers. Additionally, Kimia Bioscien., Krebs Biochem, and Pharmaids Pharma have negative six-month returns.

How big is Alpa Laboratorie?

As of 31st August, Alpa Laboratories Ltd has a market capitalization of 134.00 Cr, with recent net sales of 110.64 Cr and a net profit of 4.06 Cr. Shareholder's funds are 171.43 Cr and total assets amount to 222.63 Cr as of March 2025.

As of 31st August, Alpa Laboratories Ltd has a market capitalization of 134.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, Alpa Laboratories reported Net Sales of 110.64 Cr and a Net Profit of 4.06 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 171.43 Cr and Total Assets of 222.63 Cr.

Should I buy, sell or hold Alpa Laboratories Ltd?

Are Alpa Laboratories Ltd latest results good or bad?

Alpa Laboratories Ltd's latest results are concerning, with a 13.21% decline in net profit and a 21.34% drop in revenue year-on-year, despite improved operating margins. The company's significant underperformance compared to the pharmaceutical sector and reliance on volatile income raise doubts about its future growth prospects.

Alpa Laboratories Ltd's latest results indicate a challenging situation for the company. In Q4 FY26, the net profit was ₹1.38 crore, which represents a decline of 13.21% compared to the previous quarter. Revenue for the same quarter was ₹31.40 crore, reflecting a significant year-on-year drop of 21.34% from ₹39.92 crore in Q4 FY25. Although the operating margin improved to 11.46%, the overall financial performance is concerning due to the substantial revenue contraction.<BR><BR>The company has struggled with declining sales efficiency, as evidenced by a five-year EBIT growth rate of negative 193.44%. Additionally, Alpa Laboratories has underperformed the broader pharmaceutical sector significantly, with its stock price falling 31.77% over the past year while the sector gained 9.25%. <BR><BR>Despite returning to profitability, the reliance on volatile other income raises questions about the sustainability of this profitability. The absence of institutional investor interest and the company's low valuation multiples suggest that the market has serious concerns about its future growth prospects. <BR><BR>In summary, while there are some positive aspects, such as improved operating margins, the overall results reflect a troubling trend for Alpa Laboratories, indicating a challenging outlook ahead.

When is the next results date for Alpa Laboratories Ltd?

The next results date for Alpa Laboratories Ltd is 14 August 2026.

The next results date for Alpa Laboratories Ltd is scheduled for 14 August 2026.

Is Alpa Laboratorie overvalued or undervalued?

As of November 17, 2025, Alpa Laboratorie is considered overvalued and risky, with a PE Ratio of 9.02 and significant underperformance compared to peers like Sun Pharma and Cipla, as well as a year-to-date return of -33.37% against the Sensex's 8.72%.

As of 17 November 2025, the valuation grade for Alpa Laboratorie has moved from very attractive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE Ratio of 9.02, an EV to EBIT of -9.06, and an EV to EBITDA of -29.26, which suggest that the company's earnings and cash flows are under pressure.<BR><BR>In comparison to its peers, Alpa Laboratorie shows a stark contrast with Sun Pharma, which has a PE Ratio of 36.69 and an EV to EBITDA of 24.22, and Cipla, with a PE Ratio of 22.81 and an EV to EBITDA of 16.14. These comparisons highlight that Alpa Laboratorie is lagging behind its industry counterparts in terms of valuation metrics. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -33.37% compared to the Sensex's 8.72%, reinforcing the notion of its overvaluation.

How has been the historical performance of Alpa Laboratorie?

Alpa Laboratorie has shown steady growth in net sales and profit from Mar'20 to Mar'25, with net sales increasing from 85.97 Cr to 112.45 Cr, and profit before tax rising from 2.54 Cr to 25.67 Cr. Despite fluctuations in operating profit margins and rising raw material costs, the company's total assets and cash flow from operations have significantly improved.

Answer:<BR>The historical performance of Alpa Laboratorie shows a steady growth in net sales and profit over the years, with significant fluctuations in operating profit margins and expenses.<BR><BR>Breakdown:<BR>Alpa Laboratorie's net sales increased from 85.97 Cr in Mar'20 to 112.45 Cr in Mar'25, with a notable rise from 92.44 Cr in Mar'23 to 108.74 Cr in Mar'24. The total operating income followed a similar trend, reaching 112.45 Cr in Mar'25. However, raw material costs have also risen significantly, from 49.48 Cr in Mar'21 to 70.72 Cr in Mar'25, contributing to total expenditure growth from 82.62 Cr in Mar'20 to 107.70 Cr in Mar'25. Operating profit (PBDIT) saw fluctuations, peaking at 10.69 Cr in Mar'22 before dropping to 4.75 Cr in Mar'25. Profit before tax increased from 2.54 Cr in Mar'19 to 25.67 Cr in Mar'25, while profit after tax rose from 0.93 Cr in Mar'19 to 19.50 Cr in Mar'25, indicating improved profitability. The company's total assets grew from 120.43 Cr in Mar'20 to 222.63 Cr in Mar'25, with total liabilities also increasing from 120.43 Cr to 222.63 Cr in the same period. Cash flow from operating activities improved significantly to 18.00 Cr in Mar'25, compared to just 3.00 Cr in Mar'24, reflecting better operational efficiency. Overall, Alpa Laboratorie's financial performance demonstrates a positive growth trajectory despite rising costs and fluctuating profit margins.

Who are the top shareholders of the Alpa Laboratorie?

The top shareholders of Alpa Laboratorie include promoter Paresh Chawla with 34.26%, individual investors with 37.28%, and two foreign institutional investors holding 0.36%. There are no mutual funds or pledged promoter holdings in the company.

The top shareholders of Alpa Laboratorie are primarily its promoters, with Paresh Chawla being the individual with the highest holding at 34.26%. Additionally, individual investors collectively hold 37.28% of the shares. There are also two foreign institutional investors (FIIs) that hold a combined total of 0.36%. Notably, there are no mutual funds currently holding shares in the company, and there are no pledged promoter holdings.

What is the technical trend for Alpa Laboratorie?

As of June 5, 2025, Alpa Laboratorie's trend has shifted to bearish with moderate strength, driven by bearish MACD and moving averages, along with mixed signals from Bollinger Bands and KST.

As of 5 June 2025, the technical trend for Alpa Laboratorie has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and mildly bearish signals from Bollinger Bands and Dow Theory on both weekly and monthly time frames. The KST shows a mildly bullish trend on the weekly but remains mildly bearish monthly, indicating mixed signals. Overall, the bearish trend is reinforced by the recent price action and the performance relative to the Sensex.

Has Alpa Laboratorie declared dividend?

No Dividend History Available